Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development

Pharmacology

Volumn 79, Issue 1, 2007, Pages 42-49

  Nizri, Eran ^a   Irony Tur Sinai, Michal ^a   Grigoriadis, Nikolaos ^c   Abramsky, Oded ^a   Amitai, Gabi ^b   Brenner, Talma ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b IIBR   (Israel)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Fetoprotein; Bifunctional molecules; Central nervous system inflammation; Drug development; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Natural immunomodulating protein

Indexed keywords

ALPHA FETOPROTEIN; ANTIGEN; CHOLINESTERASE INHIBITOR; CYTISINE; DECYLPYRIDOSTIGMINE; DICLOFENAC; IBUPROFEN; IBUPROFEN OCTYLCYTISINE; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OCTYLPYRIDOSTIGMINE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; CENTRAL NERVOUS SYSTEM; CHOLINERGIC ACTIVITY; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG CONJUGATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NERVE INJURY; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR STRUCTURE; NEUROGENIC INFLAMMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845940740     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097628     Document Type: Review

References (46)

1. Schmid EF, Smith DA: Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005;10:1031-1039.
2. Van der Greef J, McBurney RN: Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961-967.
3. Kramer R, Cohen D: Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3:965-972.
4. Torr-Brown S: Advances in knowledge management for pharmaceutical research and development. Curr Opin Drug Discov Devel 2005;8:316-322.
5. Steinman L, Zamvil SS: How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12-21.
6. Hemmer B, Archelos JJ, Hartung HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
7. Steinman L: Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762-764.
8. Bjartmar C, Wujek JR, Trapp BD: Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-171.
9. Amitai G, Adani R, Rabinovitz I, Beit-Yanai E, Shohami E, Sod-Moriah G, Meshulam H: Cholinergic Mechanisms: Function and Dysfunction, Chapt 41. Newgen Imaging Systems, 2004.
10. Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, Amitai G, Inestrosa NC: The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis 2005;18:176-183.
11. Drews J: Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 2006;5:635-640.
12. Kanwar JR, Kanwar RK, Krissansen GW: Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 2004;127:1313-1331.
13. Nizri E, Adani R, Meshulam H, Amitai G, Brenner T: Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. Neurosci Lett 2005;376:46-50.
14. Moon C, Ahn M, Wie MB, Kim HM, Koh CS, Hong SC, Kim MD, Tanuma N, Matsumoto Y, Shin T: Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes. Brain Res 2005;1035:206-210.
15. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
16. Scheuren N, Bang H, Munster T, Brune K, Pahl A: Modulation of transcription factor NF-κB by enantiomers of the non-steroidal drug ibuprofen. Br J Pharmacol 1998;123:645-652.
17. Barnes PJ, Karin M: Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
18. Sacco S, Agnello D, Sottocorno M, Lozza G, Monopoli A, Villa P, Ghezzi P: Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats. J Neurochem 1998;71:2063-2070.
19. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ: Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003;421:384-388.
20. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T: Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006;50:540-547.
21. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
22. Miller NH, Hill M, Kottke T, Ockene IS: The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95:1085-1090.
23. DiMatteo MR: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-209.
24. O'Connor KA, Roth BL: Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005;4:1005-1014.
25. Salha O, Balen AH: New concepts in super-ovulation strategies for assisted conception treatments. Curr Opin Obstet Gynecol 2000;12:201-206.
26. Carrel AL, Allen DB: Effects of growth hormone on body composition and bone metabolism. Endocrine 2000;12:163-172.
27. Offner H: Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J Neurosci Res 2004;78:603-624.
28. Burrow G, Ferris T: Medical Complications during Pregnancy, Philadelphia, Saunders, 1975.
29. Da Silva J, Spector T: The role of pregnancy in the course and etiology of rheumatoid arthritis. Clin Rheumatol 1992;11:189-194.
30. Olding LB, Papadogiannakis N, Barbieri B, Murgita RA: Suppressive cellular and molecular activities in maternofetal immune interactions; suppressor cell activity, prostaglandins, and α-fetoproteins. Curr Top Microbiol Immunol 1997;222:159-187.
31. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-291.
32. Ciafaloni E, Massey JM: Myasthenia gravis and pregnancy. Neurol Clin 2004;22:771-782.
33. Brenner T, Abramsky O, Lisak RP: Influence of α-fetoprotein on the in vitro and in vivo immune response to acetylcholine receptor. Ann NY Acad Sci 1981;377:208-221.
34. Brenner T, Zielinski A, Argov Z, Abramsky O: Prevention of experimental autoimmune myasthenia gravis in rats by fetal α-fetoprotein-rich fractions. Tumour Biol 1984;5:263-274.
35. Andresen RH, Monroe CW: Experimental study of the behavior of adult human skin homografts during pregnancy. A preliminary report. Am J Obstet Gynecol 1962;84:1096-1103.
36. Gleicher N, Cohen CJ, Deppe G, Gusberg SB: Familial malignant melanoma of the female genitalia: a case report and review. Obstet Gynecol Surv 1979;34:1-15.
37. Evron S, Brenner T, Abramsky O: Suppressive effect of pregnancy on the development of experimental allergic encephalomyelitis in rabbits. Am J Reprod Immunol 1984;5:109-113.
38. Morell V: Zeroing in on how hormones affect the immune system. Science 1995;269:773-775.
39. Bebo BF Jr, Dveksler GS: Evidence that pregnancy specific glycoproteins regulate T-cell function and inflammatory autoimmune disease during pregnancy. Curr Drug Targets Inflamm Allergy 2005;4:231-237.
40. Harness J, Cavanagh A, Morton H, Mc-Combe P: A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J Neurol Sci 2003;216:33-41.
41. Langer-Gould A, Garren H, Slansky A, Ruiz PJ, Steinman L: Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factor. J Immunol 2002;169:1084-1091.
42. Mishan-Eisenberg G, Borovsky Z, Weber MC, Gazit R, Tykocinski ML, Rachmilewitz J: Differential regulation of Th1/Th2 cytokine responses by placental protein 14. J Immunol 2004;173:5524-5530.
43. Abramsky O, Brenner T, Mizrachi R, Soffer D: Alpha-fetoprotein suppresses experimental allergic encephalomyelitis. J Neuroimmunol 1982;2:1-7.
44. Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T: Amelioration of autoimmune neuroinflammation by recombinant human α-fetoprotein. Exp Neurol 2006;198:136-144.
45. Suzuki Y, Zeng CQ, Alpert E: Isolation and partial characterization of a specific α-fetoprotein receptor on human monocytes. J Clin Invest 1992;90:1530-1536.
46. Torres JM, Laborda J, Naval J, Darracq N, Calvo M, Mishal Z, Uriel J: Expression of α-fetoprotein receptors by human T lymphocytes during blastic transformation. Mol Immunol 1989;26:851-857.